I am ready for a long road flight for work with a week- or months-long projects.
Any question about our company, a partnership, or job opportunities?
Please complete our contact form and we will get in touch ASAP
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
Our collaborators
Get GERO.AI presentation
Please notice, we will consider providing you with a presentation only If you use your full name and corporate e-mail.
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
Get GERO.AI presentation
Please notice, we will consider providing you with a presentation only If you use your full name and corporate e-mail.
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
We Invite You to Discover Revolutionary Drugs Together
Gero.ai
We are scientists, this is why we value collaboration.
If you are a pharmaceutical company who is looking for novel drugs targeting age-related diseases, do not hesitate to contact us.
If you are a pharmaceutical company who is looking for novel drugs targeting age-related diseases, do not hesitate to contact us.
Any question about our company, a partnership, or job opportunities?
Please complete our contact form and we will get in touch ASAP
By clicking submit below, you consent to allow Gero to store and process the personal information submitted above to provide you the content requested.
We’ve built Large Health Models (LHMs) using longitudinal real world human data
Our Approach
Unsupervised training methods that can predict future health outcomes akin to how Large Language Models (LLMs) can predict the next word in a sentence. Unlike LLMs, LHMs are physics-based and hence fully interpretable. In, and, in conjunction with genetics, LHMs revealing new treatments for chronic age-related diseases and new means of patient stratification.
Hacking aging
Aging is a natural part and the "last mile" of a human development program, and Gero pioneer ways to understand, measure, and, ultimately, control its progression.
Our Science
Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases
— "We are excited to work with Pfizer, one of the world’s leading biopharmaceutical companies, to potentially identify targets against fibrotic diseases, which have a large unmet need. We believe that combining our platform technology with Pfizer’s extensive disease expertise has the potential to identify high-value targets in this disease area."
Alex Kadet, CBO of Gero.
Alex Kadet, CBO of Gero.
Collaborations
Gero in media